about
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationA new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia.Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases.Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.Functional analysis of the NUP98-CCDC28A fusion protein.A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model.Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.Activating mutations in human acute megakaryoblastic leukemia.Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation.Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha.NUP98-MLL fusion in human acute myeloblastic leukemia.Identification of GSX2 and AF10 as NUP98 partner genes in myeloid malignancies.Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells.AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.Familial hematological malignancies: new IDH2 mutation.SRF selectively controls tip cell invasive behavior in angiogenesis.IDH1, Histone Methylation, and So Forth.Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice.Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.NUP98–HMGB3: a novel oncogenic fusionHOX11L2/TLX3 is transcriptionally activated through T-cell regulatory elements downstream of BCL11B as a result of the t(5;14)(q35;q32)Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenibThe serum response factor (SRF)/megakaryocytic acute leukemia (MAL) network participates in megakaryocyte developmentMutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutationsCoordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis
P50
Q27684364-FB3968C2-0AF2-4034-B850-D25228213626Q33182502-3E7B6D34-6D6F-4252-8FF9-E350BF78486CQ34870666-F085F153-1FB9-4836-B626-77D9BCE1CB92Q35068764-3663AD94-E389-4176-88C3-920D4E165021Q35794430-DCD0C786-CC15-4CFC-B44F-B5A471EE75B0Q37341931-B0185A9C-1B81-4A2A-969C-5AB949446A0CQ38674045-ED9F65EE-210E-41E8-8568-6E73FBBDD107Q38774198-CCA7CA50-9E24-4664-B117-12B808F4D060Q39945867-CD3F9116-26E8-4182-B16E-ED5871B171FFQ40215071-B9EB0DD6-1A22-4227-915D-7031C1EA778CQ40235633-8E01D94E-8914-49FA-A86D-13A3D683A392Q40325416-6C4C41CF-0A7E-43B6-9AEF-A9FF368A1308Q43014158-D487021C-D7FA-4AD0-9B6D-37BBCD625CCCQ43065578-00C865BC-62D6-4D2D-BB63-18CAA664E62CQ43539014-732FD1CE-8814-478E-B726-975E3CE94F6CQ44846620-C3BE8A35-E3AF-407F-A39E-EFE4EC1F3FE2Q46677889-8DF58321-3B1E-4D91-89C4-2C5116EE6D70Q50744342-2B6535E1-E0B0-4590-A459-34446A5A541EQ51582514-60E4C96D-64E7-4662-9617-B7B3BFE9322AQ51852906-54DE3ECE-4272-4660-BBA6-01D6746412CDQ52579090-D1867D2A-BF53-483C-9346-7A1FDA1D8150Q57757902-CB20A2A9-A014-4283-ABF7-B364B086DD70Q57757938-232546B2-22B5-4E1E-862F-D901350CA367Q58042774-7751E045-CBE9-45EC-ABC2-196BAB4E8DD8Q84127652-F3AADDC7-B33E-4EBD-A67D-C13254C722ABQ87873967-D064FE15-9CF1-40C6-8FAE-A3F378CE7AB4Q90442116-47594247-EC6A-4448-883F-E12971EB1FE1
P50
description
researcher, ORCID id # 0000-0001-9435-7331
@en
wetenschapper
@nl
name
Virginie Penard-Lacronique
@ast
Virginie Penard-Lacronique
@en
Virginie Penard-Lacronique
@es
Virginie Penard-Lacronique
@nl
type
label
Virginie Penard-Lacronique
@ast
Virginie Penard-Lacronique
@en
Virginie Penard-Lacronique
@es
Virginie Penard-Lacronique
@nl
prefLabel
Virginie Penard-Lacronique
@ast
Virginie Penard-Lacronique
@en
Virginie Penard-Lacronique
@es
Virginie Penard-Lacronique
@nl
P106
P21
P31
P496
0000-0001-9435-7331